Showing 15 posts of 150 posts found.


Lilly and Boehringer’s Jardiance reduces hospitalisation and CV death risk from heart failure at Phase 3

July 30, 2020
Research and Development Boehringer, Eli Lilly, jardiance, pharma

Boehringer Ingelheim and Eli Lilly have announced strong Phase 3 news on their sodium-glucose co-transporter-2 (SGLT2) inhibitor Jardiance (empagliflozin) in …


Boehringer withdraws its £700m investment in Hikma Pharmaceuticals

June 23, 2020
Manufacturing and Production, Sales and Marketing Boehringer, Hikma

Boehringer has revealed that it intends to withdraw its investment from Hikma Pharmaceuticals, with the company poised to sell 28 …


Boehringer’s TKI inhibitor Ofev gets FDA approval for chronic fibrosing interstitial lung diseases with a progressive phenotype

March 10, 2020
Manufacturing and Production, Sales and Marketing Boehringer, FDA, ofev, pharma

The FDA has green-lit Boehringer Ingelheim’s multi-targeted tyrosine kinase inhibitor Ofev (nintedanib) in the treatment of chronic fibrosing interstitial lung …


Boehringer’s Pradaxa fails to meet Phase 3 endpoint in preventing recurrent stroke

May 20, 2019
Research and Development, Sales and Marketing Boehringer, Pradaxa, pharma, stroke, trial failure

Boehringer has announced that Pradaxa (dabigatran etexilate mesylate) has failed to meet its primary endpoint in its Phase 3 study, …


Lilly and Boehringer’s Trajenta matches glimepiride in delaying cardiovascular events in type 2 diabetes patients

February 15, 2019
Medical Communications, Research and Development Boehringer, Eli Lilly, cardiovascular disease, pharma, type 2 diabetes

Boehringer Ingelheim and Eli Lilly’s Trajenta (linagliptin) met its primary endpoint in a recent trial, it has emerged, proving itself …


Verona’s shares drop 34% on Phase 2 failure of nebulised ensifentrine in COPD

January 15, 2019
Manufacturing and Production, Research and Development Boehringer, COPD, Stiolto Respimat, pharma, trial failure, verona pharma

Verona Pharma has seen its shares crater following the Phase 2 failure of its nebulised ensifentrine, known as RPL554, in …


Top Ten most popular articles on this week!

December 14, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Akorn, Boehringer, Novartis, Pfizer, Trump, UK, pharmafile, top 10

Business seemed to be the theme this week as Akorn’s acquisition of Fresenius fell through, while Boehringer announced a restructuring …


Boehringer’s France restructure will cull over 300 jobs

December 11, 2018
Manufacturing and Production Boehringer, Sanofi, job cuts, pharma

Boehringer Ingelheim is set to follow in the recent steps of Sanofi with the announcement of a cull of over …


Boehringer signs $300 million deal with Epizyme over epigenetic cancer treatment

November 16, 2018
Medical Communications Boehringer, Cancer, Epizyme, deal, oncology

German firm Boehringer Ingelheim and the Massachusetts-based biotech Epizyme have announced that they will collaborate on the development of novel, …

Boehringer teams up with OSE in €1.1 billion cancer drug partnership

April 5, 2018
Sales and Marketing Boehringer, Cancer, OSE Immunotherapeutics, partnership, pharma

Boehringer Ingelheim and biotech firm OSE Immunotherapeutics have announced that they have entered an exclusive collaboration and license agreement to …


Boehringer loses CFO over financial strategy dispute

December 18, 2017
Medical Communications, Sales and Marketing Boehringer, Boehringer Ingelheim, appointment, pharma

Boehringer Ingelheim is set to part ways with its Chief Financial Officer Simone Menne after 16 months due to fundamental …


Boehringer celebrates EU approval of Humira biosimilar

November 14, 2017
Manufacturing and Production, Sales and Marketing Boehringer, Boehringer Ingelheim, Cyltezo, EU, Europe, European Commission, Humira, biosimilar

Boehringer Ingelheim has announced that Cyltezo, its biosimilar of Abbvie’s Humira, has received marketing authorisation approval from the European Commission, …

Sanofi BI logos

Pharma giants Sanofi and Boehringer negotiate deal to swap assets

December 15, 2015
Business Services, Manufacturing and Production, Sales and Marketing Andreas Barner, Boehringer, Boehringer Ingelheim, Merial, Sanofi, olivier brandicourt

Two of the world’s biggest pharma companies – Sanofi and Boehringer Ingelheim – have entered into exclusive negotiations to swap …

Latest content